Explore immunotherapy discoveries, treatment approvals and milestones.
See Our Breakthroughs
Working to make a difference in the lives of all affected by cancer.
Learn About Our Work
Learn more about this revolutionary cancer treatment.
Understand the Basics
Meet the CRI scientists committed to the development of immunotherapy.
Two weeks ago, we reported that pembrolizumab worked well as first-line treatment for advanced lung cancer patients. Those benefits―which included a 40% reduction in risk of death compared to chemotherapy―led the FDA to grant Breakthrough Therapy Designation and Priority Review to the therapy.
Although the FDA had until December 24 to make a decision, U.S. regulators decided yesterday, two months ahead of schedule, to approve pembrolizumab (Keytruda ®, Merck) as a first-line option for patients with advanced non-small cell lung carcinoma (NSCLC). It’s important to note, however, that this approval is for patients whose tumors have high PD-L1 expression (more than half the cells expressed it) and don’t have any mutations in EGFR or ALK. Pembrolizumab is an anti-PD-1 checkpoint antibody that targets the PD-1/PD-L1 pathway and can help keep immune cells active against cancer.
FDA Approves Another Immunotherapy Option for Patients with Advanced Lung Cancer
Read Previous Article
CNN Highlights Cancer Immunotherapy Advances, CRI’s Pioneering Role
Read Next Article
National Headquarters | One Exchange Plaza
55 Broadway, Suite 1802 | New York, NY 10006
(800) 992-2623(212) 832-9376Staff Directory
Atezolizumab’s third approval in the last year provides an important treatment option for a neglected population of patients with bladder cancer
TIME magazine honors Dr. Allison’s development of the first checkpoint immunotherapy, which has led to a revolution in cancer treatment.